Overview

Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Collaborator:
Procter and Gamble
Treatments:
Darifenacin